Dermata Therapeutics (DRMA) Stock: Buy, Sell, or Hold?
DRMA - Dermata Therapeutics, Inc. Common Stock
$0.84
0.04 (4.44%)
▲
5d:
-8.24%
30d:
-25.45%
90d:
-36.74%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 13, 2026
21d
Get Alerted When DRMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DRMA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DRMA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DRMA is currently trading at $0.83, which is considered oversold relative to its 30-day fair value range of $0.94 to $1.20.
Technical Outlook: Technically, DRMA is in a downtrend. Immediate support is located at $0.60, while resistance sits at $1.18. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: DRMA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+400.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DRMA is in a downtrend. Immediate support is located at $0.60, while resistance sits at $1.18. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: DRMA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+400.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.94 -
$1.20
Company Quality Score
51/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 400.3% below Wall St target ($4.00)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.94 -
$1.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.60
Resistance Level
$1.18
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.56
Wall Street Target
$4.00
(+400.3%)
Share & Embed Analysis
Last updated: October 22, 2026 10:17 AM ET
Data refreshes hourly during market hours. Next update: 11:17 AM
Data refreshes hourly during market hours. Next update: 11:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 70 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 51 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 58 HOLD |
